What resulted from a meeting between Food Allergy Canada and the fast-food chain.
Simon-Pierre Canuel speaks out about the painful criticism he faced after waiter’s arrest.
Mother-of-three Christina Casado had never heard of an epinephrine auto-injector, until the device was used to save her son’s life.
Amid a firestorm of controversy over price hikes on lifesaving EpiPens, drug manufacturer Mylan made a dramatic and unusual move this week – it announced the launch of a lower cost generic replica of its own brand-name epinephrine auto-injector.
Ten years ago my foray into the world of food allergies began when my first born, Julian, was diagnosed with peanut allergy just months before starting junior kindergarten. Looking back, I’m amazed to see how far we’ve come as a society to address an issue affecting a growing number of children. In January 2006, Sabrina’s… Read more »
From blogs to the press to esteemed medical journals, those who support anaphylaxis policies in schools are being branded as “hysterical” or “fearful” or even needing to “feel special”. Exceptional anxiety is portrayed as the rule. AL bites into: why critics love to hate food allergy.
Mylan’s new generic 2-pack carton will list for about $300 at pharmacies.
To see the U.S. edition click here. Special Report: Meet the researchers who are convinced that gut microbes hold the key to preventing – or even curing – allergies. Features: Divine allergy-friendly s’mores, cookies & fairy cakes; dating with allergies; celiac’s itchy rash; and more! News: Breakthrough on possible allergy therapy, backlash to Quebec diner who sued… Read more »
To see the Canadian edition click here. Special Report: Meet the researchers who are convinced that gut microbes hold the key to preventing – or even curing – allergies. Features: Divine allergy-friendly s’mores & cookies; dating with allergies; auto-injector competition arrives; celiac’s itchy rash; and more! News: Lawsuit settles for $15 million, breakthrough on possible therapy, backlash for… Read more »
Lawmakers had charged EpiPen maker was significantly underpaying program.